Cardlytics (CDLX) Scheduled to Post Quarterly Earnings on Tuesday

Cardlytics (NASDAQ:CDLX) will be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.23. The firm had revenue of $48.73 million during the quarter, compared to analysts’ expectations of $43.77 million. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The company’s quarterly revenue was up 37.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.21) EPS. On average, analysts expect Cardlytics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CDLX opened at $40.01 on Friday. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.79. Cardlytics has a 1-year low of $9.80 and a 1-year high of $42.19. The firm has a 50-day moving average price of $36.89 and a two-hundred day moving average price of $29.43. The stock has a market capitalization of $928.40 million, a PE ratio of -18.70 and a beta of 1.56.

A number of research analysts have weighed in on the stock. ValuEngine lowered shares of Cardlytics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. set a $43.00 price objective on shares of Cardlytics and gave the stock a “buy” rating in a research report on Friday, August 9th. Bank of America reissued a “buy” rating and issued a $32.00 price objective (up previously from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. Zacks Investment Research lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Finally, Raymond James boosted their price objective on shares of Cardlytics from $24.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $34.86.

In other news, CFO David Thomas Evans sold 5,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $40.98, for a total value of $204,900.00. Also, COO Lynne Marie Laube sold 1,460 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $31.91, for a total transaction of $46,588.60. The disclosure for this sale can be found here. In the last three months, insiders bought 316,475 shares of company stock worth $11,914,849 and sold 2,649,922 shares worth $83,318,325. Insiders own 21.90% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: Why is cost of goods sold important?

Earnings History for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.